docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-8-33-39docru-235Research ArticleКАРДИОМЕТАБОЛИЧЕСКАЯ МЕДИЦИНАCARDIOMETABOLIC MEDICINEПациенты «особого» сердечно-сосудистого риска. Современные аспекты необходимости профилактического мониторинга молодых лиц с низкой выраженностью предикторов сердечно-сосудистых заболеванийPatients with "Special" Cardiovascular Risk. Modern Aspects of the Need for Preventive Monitoring of Young People with Low Severity of Predictors of Cardiovascular Diseaseshttps://orcid.org/0009-0004-3541-8922КисиленкоЕ. В.KisilenkoE. V.

Кисиленко Евгения Вадимовна - врач-терапевт приемного отделения

198013, г. Санкт-Петербург, Загородный пр-т, д. 47

47 Zagorodny Prosp, St. Petersburg, 198013

evgeniakisilenko@yandex.ruhttps://orcid.org/0000-0003-1908-7954СоболевА. Д.SoboleA. D.

Соболев Алексей Дмитриевич - к. м. н., преподаватель кафедры военно-морской терапии

198013, г. Санкт-Петербург, Загородный пр-т, д. 47

47 Zagorodny Prosp, St. Petersburg, 198013

sobolevvmeda@rambler.ruhttps://orcid.org/0000-0003-1363-6860ЧеркашинД. В.CherkashinD. V.

Черкашин Дмитрий Викторович - д. м. н., профессор, начальник кафедры военно-морской терапии

198013, г. Санкт-Петербург, Загородный пр-т, д. 47

47 Zagorodny Prosp, St. Petersburg, 198013

cherkashin_dmitr@mail.ruФГБВОУ ВО «Военно-медицинская академия имени С.М. Кирова» Министерства обороны Российской ФедерацииРоссияS.M. Kirov Military Medical AcademyRussian Federation202318022025228КАРДИОМЕТАБОЛИЧЕСКАЯ МЕДИЦИНА3339Copyright © Кисиленко Е.В., Соболев А.Д., Черкашин Д.В., 20252025Кисиленко Е.В., Соболев А.Д., Черкашин Д.В.Kisilenko E.V., Sobole A.D., Cherkashin D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/235

Цель. Обзор литературы по актуальным вопросам возможных осложнений применения андрогенных анаболических стероидов (ААС) со стороны сердечно-сосудистой системы и роли злоупотребления ААС в повышении индивидуального сердечно-сосудистого риска.Основные положения. В статье отражены исторические этапы применения ААС. Установлены основные патофизиологические механизмы развития нежелательных эффектов со стороны сердечно-сосудистой системы. Предложены потенциальные стратегии снижения риска развития побочных эффектов и осложнений со стороны системы кровообращения.Заключение. Отмечается тенденция неуклонно растущего потребления ААС в отсутствие медицинских рекомендаций и контроля, что создает значительные предпосылки для увеличения сердечно-сосудистого риска у лиц, занимающихся рекреационной физической нагрузкой, не попадающих в поле зрения профилактической кардиологии.

Aim. To review the literature on topical issues of possible complications of the use of androgenic anabolic steroids (AAS) from the cardiovascular system and the role of abuse of AAS in increasing individual cardiovascular risk.Key points. The article reflects the historical stages of the application of AAS. The main pathophysiological mechanisms of the development of undesirable effects from the cardiovascular system have been established. Potential strategies for reducing the risk of side effects and complications from the circulatory system are proposed.Conclusion. There is a trend of steadily increasing consumption of AAS in the absence of medical recommendations and control, which creates significant prerequisites for increasing cardiovascular risk in people engaged in recreational physical activity who do not fall into the field of preventive cardiology.

андрогенные анаболические стероидытестостеронсердечно-сосудистая системапобочные эффектыосложнениястратегии снижения рискаandrogenic anabolic steroidstestosteronecardiovascular systemside effectscomplicationsrisk reduction strategiesReferencesРоссийский национальный конгресс кардиологов Кардиология 2022: новая стратегия в новой реальности — открытость, единство, суверенитет: 29 сентября – 1 октября 2022 года, Казань. Казань; 2022. 787 с.Russian National Congress of Cardiologists Cardiology 2022: a new strategy in a new reality — openness, unity, sovereignty: September 29 – October 1, 2022, Kazan. Kazan; 2022. 787 p. (in Russian)Концевая А.В., Муканеева Д.К., Мырзаматова А.О. и др. Экономический ущерб факторов риска в Российской Федерации в 2016 году. Кардиоваскулярная терапия и профилактика. 2020;19(1):48–55.Kontsevaya A.V., Mukaneeva D.K., Myrzamatova A.O. et al. Economic damage of risk factors associated with morbidity and mortality from major chronic non-communicable diseases in Russia in 2016. Cardiovascular Therapy and Prevention. 2020;19(1):48–55. (in Russian). DOI: 10.15829/1728-8800-2020-1-2396Freeman E.R., Bloom D.A., McGuire E.J. A brief history of testosterone. J. Urol. 2001;65(2):371–373. DOI: 10.1097/00005392-200102000-00004Freeman E.R., Bloom D.A., McGuire E.J. A brief history of testosterone. J. Urol. 2001;65(2):371–373. DOI: 10.1097/00005392-200102000-00004Matfin G. The rejuvenation of testosterone: philosopher’s stone or Brown-Sequard Elixir? Ther. Adv. Endocrinol. Metab. 2010;1(4):151–154. DOI: https://doi.org/10.1177/2042018810385052Matfin G. The rejuvenation of testosterone: philosopher’s stone or Brown-Sequard Elixir? Ther. Adv. Endocrinol. Metab. 2010;1(4):151–154. DOI: https://doi.org/10.1177/2042018810385052Лихоносов Н.П., Бабенко А.Ю. Распространенность использования андрогенных анаболических стероидов, их влияние на систему гипофиз-гонады у мужчин и возможности репродуктивной реабилитации. Проблемы эндокринологии. 2019;65(2):124–133.Lykhonosov M.P., Babenko A.V. Prevalence of anabolic androgenic steroid use, its eff ect on the male pituitarygonadal axis, and the possibility of reproductive rehabilitation. Problems of Endocrinology. 2019;65(2):124–133. (In Russian). DOI: https://doi.org/10.14341/probl9997Seara F.A.C., Olivares E.L., Nascimento J.H.M. Anabolic steroid excess and myocardial infarction: from ischemia to reperfusion injury. Steroids. 2020;161:108660. DOI: 10.1016/j.steroids.2020.108660Seara F.A.C., Olivares E.L., Nascimento J.H.M. Anabolic steroid excess and myocardial infarction: from ischemia to reperfusion injury. Steroids. 2020;161:108660. DOI: 10.1016/j.steroids.2020.108660Perry J.C., Schuetz T.M., Memon M.D. et al. Anabolic steroids and cardiovascular outcomes: the controversy. Cureus. 2020;12(7):e9333. DOI: 10.7759/cureus.9333Perry J.C., Schuetz T.M., Memon M.D. et al. Anabolic steroids and cardiovascular outcomes: the controversy. Cureus. 2020;12(7):e9333. DOI: 10.7759/cureus.9333Goldman A.L., Pope Jr. H.G., Bhasin S. The health threat posed by the hidden epidemic of anabolic steroid use and body image disorders among young men. J. Clin. Endocrinol. Metab. 2019;104(4):1069–1074. DOI: 10.1210/jc.2018-01706Goldman A.L., Pope Jr. H.G., Bhasin S. The health threat posed by the hidden epidemic of anabolic steroid use and body image disorders among young men. J. Clin. Endocrinol. Metab. 2019;104(4):1069–1074. DOI: 10.1210/jc.2018-01706Сердюк П.Л. О проблеме борьбы с допингом в профессиональном спорте России. M.; 2021.Serdyuk P.L. On the problem of combating doping in professional sports in Russia. Moscow; 2021. (in Russian)Лихоносов Н.П., Бабенко А.Ю. Медицинский аспект использования анаболических андрогенных стероидов у мужчин, посещающих тренажерные залы Санкт-Петербурга. Проблемы эндокринологии. 2019;65(1): 19–30.Lykhonosov M.P., Babenko A.Yu. The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint Petersburg. Problems of Endocrinology. 2019;65(1):19–30. (in Russian). DOI: https://doi.org/10.14341/probl9832Усов Е.Г., Мамедов Э.Ф., Самсонов В.А. Об обоснованности криминализации незаконного оборота анаболических стероидов. Вестник Московского университета МВД России. 2022;(2):236–238.Usov E.G., Mammedov E.F., Samsonov V.A. On the validity of the criminalization of the identified turnover anabolic steroid. Bulletin of the Moscow University of the Ministry of Internal Affairs of Russia. 2022;(2):236–238. (in Russian). DOI: 10.24412/2073-0454-2022-2-236-238Samieinasab M.R., Shahraki M.R., Samieinasab F., Najafi S. Influence of nandrolone decanoate administration on serum lipids and liver enzymes in rats. ARYA Atheroscler. 2015;11(4):256–260.Samieinasab M.R., Shahraki M.R., Samieinasab F., Najafi S. Influence of nandrolone decanoate administration on serum lipids and liver enzymes in rats. ARYA Atheroscler. 2015;11(4):256–260.Achar S., Rostamian A., Narayan S.M. Cardiac and metabolic effecоjcard.2010.05.013Achar S., Rostamian A., Narayan S.M. Cardiac and metabolic effecоjcard.2010.05.013Souza F.R., Dos Santos M.R., Porello R.A. et al. Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users. Atherosclerosis. 2019;283:100–105. DOI: 10.1016/j.atherosclerosis.2019.02.006Souza F.R., Dos Santos M.R., Porello R.A. et al. Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users. Atherosclerosis. 2019;283:100–105. DOI: 10.1016/j.atherosclerosis.2019.02.006Gonçalves R.V., Santos J.D.B., Silva N.S. et al. Trans-fatty acids aggravate anabolic steroid-induced metabolic disturbances and differential gene expression in muscle, pancreas and adipose tissue. Life Sci. 2019;232:116603. DOI: 10.1016/j.lfs.2019.116603Gonçalves R.V., Santos J.D.B., Silva N.S. et al. Trans-fatty acids aggravate anabolic steroid-induced metabolic disturbances and differential gene expression in muscle, pancreas and adipose tissue. Life Sci. 2019;232:116603. DOI: 10.1016/j.lfs.2019.116603de Andrade T.U., Haguihara S.C.G.C., Falsoni R.M.P. et al. Stanozolol promotes lipid deposition in the aorta through an imbalance in inflammatory cytokines and oxidative status in LDLr knockout mice fed a normal diet. Basic Clin. Pharmacol. Toxicol. 2019;124(4):360–369. DOI: 10.1111/bcpt.13143de Andrade T.U., Haguihara S.C.G.C., Falsoni R.M.P. et al. Stanozolol promotes lipid deposition in the aorta through an imbalance in inflammatory cytokines and oxidative status in LDLr knockout mice fed a normal diet. Basic Clin. Pharmacol. Toxicol. 2019;124(4):360–369. DOI: 10.1111/bcpt.13143Niedfeldt M.W. Anabolic steroid effect on the liver. Curr. Sports Med. Rep. 2018;17(3):97–102. DOI: 10.1249/JSR.0000000000000467Niedfeldt M.W. Anabolic steroid effect on the liver. Curr. Sports Med. Rep. 2018;17(3):97–102. DOI: 10.1249/JSR.0000000000000467Zhu D., Hadoke P.W., Wu J. et al. Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. Sci. Rep. 2016;6:24807. DOI: 10.1038/srep24807Zhu D., Hadoke P.W., Wu J. et al. Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. Sci. Rep. 2016;6:24807. DOI: 10.1038/srep24807Rosca A.E., Stancu C.S., Badiu C. et al. Lipid profile changes induced by chronic administration of anabolic androgenic steroids and taurine in rats. Medicina (Kaunas). 2019;55(9):540. DOI: 10.3390/medicina55090540Rosca A.E., Stancu C.S., Badiu C. et al. Lipid profile changes induced by chronic administration of anabolic androgenic steroids and taurine in rats. Medicina (Kaunas). 2019;55(9):540. DOI: 10.3390/medicina55090540Mogharnasi M., Cheragh-Birjandi K., Cheragh-Birjandi S., Taher-iChadorneshin H. The effects of resistance and endurance training on risk factors of vascular inflammation and atherogenesis in non-athlete men. Interv. Med. Appl. Sci. 2017;9:185–190. DOI: https://doi.org/10.1556/1646.9.2017.36Mogharnasi M., Cheragh-Birjandi K., Cheragh-Birjandi S., Taher-iChadorneshin H. The effects of resistance and endurance training on risk factors of vascular inflammation and atherogenesis in non-athlete men. Interv. Med. Appl. Sci. 2017;9:185–190. DOI: https://doi.org/10.1556/1646.9.2017.36Carson P., Hong C.J., Otero-Vinas M. et al. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial. Int. J. Low Extrem. Wounds 2015;14:11–18. DOI: https://doi.org/10.1177/1534734614562276Carson P., Hong C.J., Otero-Vinas M. et al. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial. Int. J. Low Extrem. Wounds 2015;14:11–18. DOI: https://doi.org/10.1177/1534734614562276Peoples K., Kobe D., Campana C., Simon E. Hyperhomocysteinemiainduced myocardial infarction in a young male using anabolic steroids. Am. J. Emerg. Med. 2014;32:941–948. DOI: https://doi.org/10.1016/j.ajem.2014.01.041Peoples K., Kobe D., Campana C., Simon E. Hyperhomocysteinemiainduced myocardial infarction in a young male using anabolic steroids. Am. J. Emerg. Med. 2014;32:941–948. DOI: https://doi.org/10.1016/j.ajem.2014.01.041Riezzo I., De Carlo D., Neri M. et al. Heart disease induced by AAS abuse, using experimental mice/rats models and the role of exercise-induced cardiotoxicity. Mini Rev. Med. Chem 2011;11:409–424. DOI: 10.2174/138955711795445862Riezzo I., De Carlo D., Neri M. et al. Heart disease induced by AAS abuse, using experimental mice/rats models and the role of exercise-induced cardiotoxicity. Mini Rev. Med. Chem 2011;11:409–424. DOI: 10.2174/138955711795445862Lippi G., Banfi G. Doping and thrombosis in sports. Semin. Thromb. Hemost. 2011;37:918–928. DOI: 10.1055/s-0031-1297371Lippi G., Banfi G. Doping and thrombosis in sports. Semin. Thromb. Hemost. 2011;37:918–928. DOI: 10.1055/s-0031-1297371Frati P., Busardo F.P., Cipolloni L. et al. Anabolic androgenic steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Curr. Neuropharmacol. 2015;13:146–159. DOI: 10.2174/1570159X13666141210225414Frati P., Busardo F.P., Cipolloni L. et al. Anabolic androgenic steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Curr. Neuropharmacol. 2015;13:146–159. DOI: 10.2174/1570159X13666141210225414Shamloul R.M., Aborayah A.F., Hashad A., Abd-Allah F. Anabolic steroids abuse-induced cardiomyopathy and ischaemic stroke in a young male patient. BMJ Case Rep. 2014;2014:bcr2013203033. DOI: 10.1136/bcr-2013-203033Shamloul R.M., Aborayah A.F., Hashad A., Abd-Allah F. Anabolic steroids abuse-induced cardiomyopathy and ischaemic stroke in a young male patient. BMJ Case Rep. 2014;2014:bcr2013203033. DOI: 10.1136/bcr-2013-203033Chang S., Rasmussen J.J., Frandsen M.N. et al. Procoagulant state in current and former anabolic androgenic steroid abusers. Thromb. Haemost. 2018;118:647–653. DOI: 10.1055/s-0038-1636540Chang S., Rasmussen J.J., Frandsen M.N. et al. Procoagulant state in current and former anabolic androgenic steroid abusers. Thromb. Haemost. 2018;118:647–653. DOI: 10.1055/s-0038-1636540Achar S., Rostamian A., Narayan S.M. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am. J. Cardiol. 2010;106:893–901. DOI: 10.1016/j.amjcard.2010.05.013Achar S., Rostamian A., Narayan S.M. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am. J. Cardiol. 2010;106:893–901. DOI: 10.1016/j.amjcard.2010.05.013Dhar R., Stout C.W., Link M.S. et al. Cardiovascular toxicities of performanceenhancing substances in sports. Mayo Clin. Proc. 2005;80:1307–1315. DOI: 10.4065/80.10.1307Dhar R., Stout C.W., Link M.S. et al. Cardiovascular toxicities of performanceenhancing substances in sports. Mayo Clin. Proc. 2005;80:1307–1315. DOI: 10.4065/80.10.1307Sabzi F., Faraji R. Large in-transient left ventricular thrombus due to anabolic steroid-induced cardiomyopathy. Ind. J. Crit. Care Med. 2017;21(1):51. DOI: 10.4103/0972-5229.198328Sabzi F., Faraji R. Large in-transient left ventricular thrombus due to anabolic steroid-induced cardiomyopathy. Ind. J. Crit. Care Med. 2017;21(1):51. DOI: 10.4103/0972-5229.198328Colburn S., Childers W.K., Chacon A. et al. The cost of seeking an edge: recurrent renal infarction in setting of recreational use of anabolic steroids. Ann. Med. Surg. (Lond.). 2017;14:25–28. DOI: 10.1016/j.amsu.2017.01.015Colburn S., Childers W.K., Chacon A. et al. The cost of seeking an edge: recurrent renal infarction in setting of recreational use of anabolic steroids. Ann. Med. Surg. (Lond.). 2017;14:25–28. DOI: 10.1016/j.amsu.2017.01.015Lemiński A., Kubis M., Kaczmarek K. et al. When bodybuilding goes wrongbilateral renal artery thrombosis in a long-term misuser of anabolic steroids treated with AngioJet rheolytic thrombectomy. Int. J. Environ. Res. Public Health. 2022;19(4):2122. DOI: 10.3390/ijerph19042122Lemiński A., Kubis M., Kaczmarek K. et al. When bodybuilding goes wrongbilateral renal artery thrombosis in a long-term misuser of anabolic steroids treated with AngioJet rheolytic thrombectomy. Int. J. Environ. Res. Public Health. 2022;19(4):2122. DOI: 10.3390/ijerph19042122Tashiro K., Iso Y., Tsujiuchi M. et al. Subacute stent thrombosis after primary percutaneous coronary intervention in a middle-aged anabolic steroidabusing bodybuilder. JACC Case Rep. 2020;3(4):537–541. DOI: 10.1016/j.jaccas.2020.09.038Tashiro K., Iso Y., Tsujiuchi M. et al. Subacute stent thrombosis after primary percutaneous coronary intervention in a middle-aged anabolic steroidabusing bodybuilder. JACC Case Rep. 2020;3(4):537–541. DOI: 10.1016/j.jaccas.2020.09.038Christou G.A., Christou K.A., Nikas D.N., Goudevenos J.A. Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: a case report and critical review of the literature. Eur. J. Prev. Cardiol. 2016;23(16):1785–1796. DOI: 10.1177/2047487316651341Christou G.A., Christou K.A., Nikas D.N., Goudevenos J.A. Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: a case report and critical review of the literature. Eur. J. Prev. Cardiol. 2016;23(16):1785–1796. DOI: 10.1177/2047487316651341Hernández-Guerra A.I., Tapia J., Menéndez-Quintanal L.M., Lucena J.S. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic Sci. Res. 2019;4(3):267–273. DOI: 10.1080/20961790.2019.1595350Hernández-Guerra A.I., Tapia J., Menéndez-Quintanal L.M., Lucena J.S. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic Sci. Res. 2019;4(3):267–273. DOI: 10.1080/20961790.2019.1595350Sonmez E., Turkdogan K.A., Yilmaz C. et al. Chronic anabolic androgenic steroid usage associated with acute coronary syndrome in bodybuilder. Turk. J. Emerg. Med. 2016;16:35–37. DOI: 10.1016/j.tjem.2014.11.001Sonmez E., Turkdogan K.A., Yilmaz C. et al. Chronic anabolic androgenic steroid usage associated with acute coronary syndrome in bodybuilder. Turk. J. Emerg. Med. 2016;16:35–37. DOI: 10.1016/j.tjem.2014.11.001Ferrer M., Encabo A., Marin J., Balfagon G. Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur. J. Pharmacol. 1994;252:233–241. DOI: 10.1016/0014-2999(94)90602-5Ferrer M., Encabo A., Marin J., Balfagon G. Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur. J. Pharmacol. 1994;252:233–241. DOI: 10.1016/0014-2999(94)90602-5Liu K., Shen C., Chen X. Expression of androgen receptor in coronary artery in the cases of sudden coronary death. Int. J. Clin. Exp. Pathol 2015;8: 3742–3747.Liu K., Shen C., Chen X. Expression of androgen receptor in coronary artery in the cases of sudden coronary death. Int. J. Clin. Exp. Pathol 2015;8: 3742–3747.Rasmussen J.J., Schou M., Madsen P.L. et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma? J. Hypertens. 2018;36:277–285. DOI: 10.1097/HJH.0000000000001546Rasmussen J.J., Schou M., Madsen P.L. et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma? J. Hypertens. 2018;36:277–285. DOI: 10.1097/HJH.0000000000001546D’Andrea A., Caso P., Salerno G. et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br. J. Sports Med. 2007;41:149–155. DOI: 10.1136/bjsm.2006.030171D’Andrea A., Caso P., Salerno G. et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br. J. Sports Med. 2007;41:149–155. DOI: 10.1136/bjsm.2006.030171Lenders J.W., Demacker P.N., Vos J.A. et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int. J. Sports Med. 1988;9:19–23. DOI: 10.1055/s-2007-1024972Lenders J.W., Demacker P.N., Vos J.A. et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int. J. Sports Med. 1988;9:19–23. DOI: 10.1055/s-2007-1024972Junior J.F.C.R., Silva A.S., Cardoso G.A. et al. Androgenic-anabolic steroids inhibited post-exercise hypotension: a case control study. Braz. J. Phys. Ther. 2018;22(1):77–81. DOI: 10.1016/j.bjpt.2017.07.001Junior J.F.C.R., Silva A.S., Cardoso G.A. et al. Androgenic-anabolic steroids inhibited post-exercise hypotension: a case control study. Braz. J. Phys. Ther. 2018;22(1):77–81. DOI: 10.1016/j.bjpt.2017.07.001Roşca A.E., Stoian I., Badiu C. et al. Impact of chronic administration of anabolic androgenic steroids and taurine on blood pressure in rats. Braz. J. Med. Biol. Res. 2016;49(6):e5116. DOI: 10.1590/1414-431X20165116Roşca A.E., Stoian I., Badiu C. et al. Impact of chronic administration of anabolic androgenic steroids and taurine on blood pressure in rats. Braz. J. Med. Biol. Res. 2016;49(6):e5116. DOI: 10.1590/1414-431X20165116Ferrera P.C., Putnam D.L., Verdile V.P. Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Cardiology. 1997;88:218–220. DOI: 10.1159/000177333Ferrera P.C., Putnam D.L., Verdile V.P. Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Cardiology. 1997;88:218–220. DOI: 10.1159/000177333Nieminen M.S., Ramo M.P., Viitasalo M. et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur. Heart J. 1996;17:1576–1583. DOI: 10.1093/oxfordjournals.eurheartj.a014724Nieminen M.S., Ramo M.P., Viitasalo M. et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur. Heart J. 1996;17:1576–1583. DOI: 10.1093/oxfordjournals.eurheartj.a014724Milevski S.V., Sawyer M., La Gerche A., Paratz E. Anabolic steroid misuse is an important reversible cause of cardiomyopathy: a case report. Eur. Heart J. Case Rep. 2022;6(7):ytac271. DOI: 10.1093/ehjcr/ytac271Milevski S.V., Sawyer M., La Gerche A., Paratz E. Anabolic steroid misuse is an important reversible cause of cardiomyopathy: a case report. Eur. Heart J. Case Rep. 2022;6(7):ytac271. DOI: 10.1093/ehjcr/ytac271Li C., Adhikari B.K., Gao L. et al. Performance-enhancing drugs abuse caused cardiomyopathy and acute hepatic injury in a young bodybuilder. Am. J. Mens Health. 2018;12(5):1700–1704. DOI: 10.1177/1557988318783504Li C., Adhikari B.K., Gao L. et al. Performance-enhancing drugs abuse caused cardiomyopathy and acute hepatic injury in a young bodybuilder. Am. J. Mens Health. 2018;12(5):1700–1704. DOI: 10.1177/1557988318783504Cecchi R., Muciaccia B., Ciallella C. et al. Ventricular androgenic-anabolic steroid-related remodeling: an immunohistochemical study. Int. J. Legal Med. 2017;131(6):1589–1595. DOI: 10.1007/s00414-017-1589-3Cecchi R., Muciaccia B., Ciallella C. et al. Ventricular androgenic-anabolic steroid-related remodeling: an immunohistochemical study. Int. J. Legal Med. 2017;131(6):1589–1595. DOI: 10.1007/s00414-017-1589-3Fanton L., Belhani D., Vaillant F. et al. Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits. Exp. Toxicol. Pathol. 2009;61(4):317–323. DOI: 10.1016/j.etp.2008.09.007Fanton L., Belhani D., Vaillant F. et al. Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits. Exp. Toxicol. Pathol. 2009;61(4):317–323. DOI: 10.1016/j.etp.2008.09.007

The authors declare that there are no conflicts of interest present.